EGFR mutation screening in non-small cell lung cancer: Results from an access program in Brazil.

Pontes, Lucíola de Barros; Bacchi, Carlos E.; Queiroga, Eduardo; Piha, Tony; Miranda, Paulo; Freire, Sandra Elisa de Assis; Lopes, Gilberto

doi:10.1200/jco.2014.32.15_suppl.1526

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some efforts have been made to compile data on the frequency of molecular abnormalities in Brazilian patients ( Table 2 ). 40 - 48 Overall, the data suggest that the frequency of EGFR mutations is lower in Brazil (approximately 25%) than in Asia but higher than in White populations in North America and Europe ( Figure 3 ), confirming findings from other Latin American countries. 49 It has been speculated that the ethnic background could be responsible for the distinct molecular profile seen in these instances, perhaps due to the characteristic genetic admixture seen in Brazilians, inherited from European, African, and Native American ancestors.…”

Section: Molecular Testingsupporting

confidence: 76%

Lung cancer in Brazil

2018

View full text Add to dashboard Cite

Lung cancer is one of the most incident types of cancer and a leading cause of cancer mortality in Brazil. We reviewed the current status of lung cancer by searching relevant data on prevention, diagnosis, and treatment in the country. This review highlights several issues that need to be addressed, including smoking control, patient lack of awareness, late diagnosis, and disparities in the access to cancer health care facilities in Brazil. We propose strategies to help overcome these limitations and challenge health care providers, as well as the society and governmental representatives, to work together and to take a step forward in fighting lung cancer.

show abstract

Section: Molecular Testingsupporting

confidence: 76%

Lung cancer in Brazil

2018

View full text Add to dashboard Cite

show abstract

“…The estimated number of new cases was published by INCA (the National Cancer Institute of Brazil). 2 The proportion of patients with the disease at an advanced stage and who were in a clinical condition to be able to receive first-line treatment was estimated based on the 2014 National Lung Cancer Audit in the United Kingdom and the European study of real-world treatment data published by Moro-Sibilot et al 16,17 The proportion of patients with activation of mutations in the EGFR gene was extracted from the largest database available in the literature. 18…”

Section: Estimation Of the Number Of Eligible Patientsmentioning

confidence: 99%

Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study

et al. 2019

View full text Add to dashboard Cite

Over recent decades, the incidence of cancer and the mortality that it causes have increased in developing countries such as Brazil. 1 Among all neoplasms, lung cancer presents major concern because it is a relatively frequent disease (i.e. the fourth most common type of cancer in Brazil) and presents high lethality. In Brazil, 28,220 new cases were expected in 2017; almost 25,000 were recorded in 2013. 2 Studies on the molecular biology of advanced non-small cell lung cancer (NSCLC) have led to development of directed targeted therapies that have demonstrated better clinical outcomes and fewer collateral effects, compared with platinum-doublet chemotherapy. 3-5 Epidermal growth factor receptor (EGFR) is a transmembrane receptor that conducts signals to promote cell proliferation, angiogenesis and cell immortality. 6 Treatment of advanced NSCLC with tyrosine kinase inhibitors (TKI) directed against the EGFR receptor leads to a response rate of over 50% (that of chemotherapy is approximately 35%), and a nearly 100% increase in median progression-free survival, compared with platinum-doublet chemotherapy. 3-5 On the other hand, no studies have demonstrated any increase in overall survival, compared with platinum-doublet chemotherapy, due to the high rate (about 70%) of treatment crossover between the arms of these studies. In other words, the majority of individuals included in such clinical studies received anti-EGFR TKI in first-line or second-line treatment. 3-5

show abstract

“…A prevalência das alterações nos genes EGFR e ALK em pacientes com CPNPC foi retirada de estudos brasileiros, sendo 25,5% e 4%, respectivamente (Pontes et al, 2014;Gomes et al, 2015).…”

Section: Dados Epidemiológicosunclassified